Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Mosunetuzumab With Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

NCT06453044 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06453044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06453044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Mosunetuzumab With Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
September 9, 2024
Completion date
March 14, 2028
Enrollment
41 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3a follicular lymphoma, refractory grade 1 follicular lymphoma, refractory grade 2 follicular lymphoma, refractory grade 3a follicular lymphoma